Neuralace

A Dynamic Leap Forward for
Chronic Pain Management

This is Axon Therapy® mPNS, the 100% non-invasive treatment device for chronic nerve pain.

Axon Therapy magnetic Peripheral Nerve Stimulation (mPNS) represents a paradigm shift for treating chronic neuropathic pain. Discover the electroceutical platform rewriting the approach to neuromodulation.

Magnetic Peripheral Nerve Stimulation
(mPNS)

Bedder M, Parker L.
Magnetic Peripheral Nerve Stimulation (mPNS)
for Chronic Pain. J Pain Res. 2023;16 : 2365-2373

AXON THERAPY mPNS AT A GLANCE

What if You Could Treat More
Patients With Neuromodulation?

Axon Therapy mPNS is changing lives every day without needles, scalpels, implants, or ablations. With our pain-free platform, you can expand the benefits of neuromodulation to a larger patient community.

0 %
Non-invasive and painless spot treatments
0 %
Avg. pain reduction after complete treatment protocol 1
0 %
Avg. pain reduction after just one treatment 1
0 min
Avg. time per treatment in established protocol
0
High-frequency magnetic pulses delivered per treatment
1 For respondent patients only, VA Augusta Clinical Equipment Evaluation (CEC)

THE AXON ADVANTAGE

Welcome to a Turning
Point in Chronic Pain
Management

Axon Therapy mPNS represents the first completely non-invasive neuromodulation platform. With its high-intensity magnetic field, mPNS can be administered at skin level or even above skin level. There are no leads, no injections, no surgical implants, no risks of infection, and no therapeutic interruptions due to lead fracture or battery issues.

FIND OUT MORE
After only one treatment, Axon Therapy mPNS begins reconditioning the central nervous system by eliminating noxious pain signals to the brain. By contrast to conventional PNS, Axon Therapy uses magnetic stimulation to engage sensory, pain, and motor fibers mechanistically, providing long-term relief for the root cause of post-trauma and post-surgical neuropathic pain.

  FIND OUT MORE
Until Axon Therapy mPNS, treating chronic neuropathic pain generally boiled down to medications or intervention. Now, with its innovative mechanism of action, Axon Therapy mPNS offers a more stepwise approach to patient management compared to more intensive forms of neuromodulation such as PNS.

  FIND OUT MORE
Axon Therapy represents a breakthrough for chronic neuropathic pain management that can minimize dependence on opioids and other medications with potentially adverse side effects by an average of 51%. Improving quality of life for patients, while mitigating the risks of opioid addiction and overdose.

  FIND OUT MORE
At Neuralace Medical, we are the first to configure a high-intensity magnetic field into such a small physical footprint. It’s the only mPNS mechanism of action that is FDA-cleared for post-surgery and post-trauma neuromodulation, and with ongoing clinical research, we’re confident it will gain FDA clearance for even more indications.

  FIND OUT MORE
Neuralace Medical is a team of doctors, scientists, advisors, and veterans with a unique blend of expertise in pain management. Our vast experience in neuromodulation technology and chronic neuropathic pain treatment emboldens our mission to free the world from chronic neuropathic suffering.

  MEET OUR TEAM

SIGNIFICANT CLINICAL TRIAL RESULTS

The Treatment is Simple.
The Results Are Profound.

The Neuralace SEAT (Safety and Efficacy of Axon Therapy) RCT demonstrates significant effects at the 90-day primary endpoint, with both the physics and mechanism of action supported by hard data.

ABOUT US

With Every Magnetic
Pulse, We’re Changing
Lives

Meet the team employing painless magnetic pulses to revolutionize chronic neuropathic pain management for patients and healthcare providers.

Find Out More About Axon Therapy mPNS

JUST IN!

FDA Approval Granted for PDN

Neuralace celebrates a groundbreaking achievement with recent FDA clearance for its cutting-edge magnetic Peripheral Nerve Stimulation (mPNS) device designed to alleviate the effects from Painful Diabetic Neuropathy (PDN). This clearance signifies a pivotal moment in neurostimulation, offering a non-invasive and targeted solution for the millions affected by PDN.

Keith Warner

Chief Executive Officer

Proactive and engaging leader with expertise in advanced strategy development and implementation driving outstanding corporate growth. Over 25 years of senior level business acumen gained through key executive positions with leading large cap to venture stage startups within the life sciences and medical technology sectors. Experience in organization-building geared to achieve near and long term milestones both in domestic and international settings. Ability to deliver significant transformation and growth in financial performance, product development, investor fundraising, capital restructuring, P&L management, and strategic planning.